同种异体造血干细胞移植治疗慢性髓性白血病后与原发性移植物衰竭和移植物功能严重不良相关的移植前后因素

Q4 Medicine
E. Morozova, T. Rudakova, J. Vlasova, M. Barabanshchikova, Tatiana Gindina, A. Alyanskiy, M. Vladovskaya, I. Moiseev, L. Zubarovskaya, A. Kulagin
{"title":"同种异体造血干细胞移植治疗慢性髓性白血病后与原发性移植物衰竭和移植物功能严重不良相关的移植前后因素","authors":"E. Morozova, T. Rudakova, J. Vlasova, M. Barabanshchikova, Tatiana Gindina, A. Alyanskiy, M. Vladovskaya, I. Moiseev, L. Zubarovskaya, A. Kulagin","doi":"10.18620/ctt-1866-8836-2022-11-1-13-23","DOIUrl":null,"url":null,"abstract":"Summary Allogeneic stem cell transplantation (allo-HSCT) is used worldwide for long-term management and cure of hematological malignancies, still remaining a valuable option for treatment of chronic myeloid leukemia (CML) in all fit patients who are unable to achieve a durable complete cytogenetic response after treatment with tyrosine kinase inhibitors (TKIs), and in advanced-phase disease. Along with relapse risk, the unfavorable HSCT results may be associated with primary graft failure (PrGF), or poor graft function (PoGF). Hence, the aim of our study was to assess frequency and outcome of PrGF and severe poor graft function (sPGF) after allo-HSCT in CML patients.","PeriodicalId":39111,"journal":{"name":"Cellular Therapy and Transplantation","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Pre- and post-transplantation factors associated with primary graft failure and severe poor graft function after allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia\",\"authors\":\"E. Morozova, T. Rudakova, J. Vlasova, M. Barabanshchikova, Tatiana Gindina, A. Alyanskiy, M. Vladovskaya, I. Moiseev, L. Zubarovskaya, A. Kulagin\",\"doi\":\"10.18620/ctt-1866-8836-2022-11-1-13-23\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Summary Allogeneic stem cell transplantation (allo-HSCT) is used worldwide for long-term management and cure of hematological malignancies, still remaining a valuable option for treatment of chronic myeloid leukemia (CML) in all fit patients who are unable to achieve a durable complete cytogenetic response after treatment with tyrosine kinase inhibitors (TKIs), and in advanced-phase disease. Along with relapse risk, the unfavorable HSCT results may be associated with primary graft failure (PrGF), or poor graft function (PoGF). Hence, the aim of our study was to assess frequency and outcome of PrGF and severe poor graft function (sPGF) after allo-HSCT in CML patients.\",\"PeriodicalId\":39111,\"journal\":{\"name\":\"Cellular Therapy and Transplantation\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-04-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cellular Therapy and Transplantation\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.18620/ctt-1866-8836-2022-11-1-13-23\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cellular Therapy and Transplantation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18620/ctt-1866-8836-2022-11-1-13-23","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 1

摘要

同种异体干细胞移植(Allogeneic stem cell transplantation, alloo - hsct)在世界范围内被用于血液系统恶性肿瘤的长期治疗和治愈,对于在接受酪氨酸激酶抑制剂(TKIs)治疗后无法获得持久的完全细胞遗传学应答的所有适合的慢性髓性白血病(CML)患者和晚期疾病患者,仍然是一种有价值的治疗选择。伴随复发风险,不良的HSCT结果可能与原发性移植物衰竭(PrGF)或移植物功能不良(PoGF)有关。因此,我们研究的目的是评估CML患者同种异体造血干细胞移植后PrGF和严重移植功能不良(sPGF)的频率和结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Pre- and post-transplantation factors associated with primary graft failure and severe poor graft function after allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia
Summary Allogeneic stem cell transplantation (allo-HSCT) is used worldwide for long-term management and cure of hematological malignancies, still remaining a valuable option for treatment of chronic myeloid leukemia (CML) in all fit patients who are unable to achieve a durable complete cytogenetic response after treatment with tyrosine kinase inhibitors (TKIs), and in advanced-phase disease. Along with relapse risk, the unfavorable HSCT results may be associated with primary graft failure (PrGF), or poor graft function (PoGF). Hence, the aim of our study was to assess frequency and outcome of PrGF and severe poor graft function (sPGF) after allo-HSCT in CML patients.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Cellular Therapy and Transplantation
Cellular Therapy and Transplantation Medicine-Transplantation
CiteScore
0.60
自引率
0.00%
发文量
31
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信